Who
Jean-Pierre Bizzari
Director
Company insider
Files Form 4 as: Director, Aprea Therapeutics; Director, ADC Therapeutics SA; Director, Halozyme Therapeutics; Director, Palvella Therapeutics; Director, Celator Pharmaceuticals.
In numbers
- Trades disclosed
- 36
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.5M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 17 Jan 2015
- Last trade
- 16 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,135 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,555 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,555 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,135 at $0.00 | filing |
| 3 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $39K12,600 at $3.08 | filing |
| 3 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $39K12,600 at $3.08 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 13 Jun 2025filed 17 Jun 2025 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $45K12,600 at $3.58 | filing |
| 5 Jun 2025filed 9 Jun 2025 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,185 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,045 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 17 Jun 2024filed 18 Jun 2024 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Sold | $20K6,995 at $2.89 | filing |
| 13 Jun 2024filed 14 Jun 2024 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 23 Aug 2023filed 24 Aug 2023 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 5 May 2023filed 9 May 2023 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,371 at $0.00 | filing |
| 5 May 2023filed 9 May 2023 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —8,065 at $0.00 | filing |
| 5 May 2022filed 6 May 2022 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,206 at $0.00 | filing |
| 25 Aug 2021filed 25 Aug 2021 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M35,000 at $41.01 | filing |
| 5 May 2021filed 6 May 2021 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,230 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.